BioCentury
ARTICLE | Product Development

Poor bioavailability pays off

March 6, 2006 8:00 AM UTC

Microbia Inc. says its $75 million series E round will give the company more cash than it probably needs to bring its Phase II compound for gastrointestinal disorders and Phase I cholesterol product to market, providing the leverage it needs to compete for the right kind of development and financing deals down the road.

The company says that in addition to their market potential, the relatively low risk profile of its pipeline was key to inspiring the confidence of its investors, which included some well known hedge funds...